Literature DB >> 30700659

Steroid Cell Ovarian Tumor in a Case of von Hippel-Lindau Disease: Demonstrating Lipid Content of the Mass with MR Imaging.

Ajaykumar C Morani1, Ahmad Iyad Mubarak1, Hrishabh R Bhosale2, Nisha S Ramani3, Steven G Waguespack4, Anita Ying4.   

Abstract

Entities:  

Keywords:  lipid cell tumor; lipoid cell tumor; magnetic resonance imaging; steroid cell tumor; von Hippel–Lindau disease

Year:  2019        PMID: 30700659      PMCID: PMC6883090          DOI: 10.2463/mrms.ci.2018-0104

Source DB:  PubMed          Journal:  Magn Reson Med Sci        ISSN: 1347-3182            Impact factor:   2.471


× No keyword cloud information.
Steroid cell tumors of the ovary are rare, functioning sex cord-stromal ovarian tumors.[1] Previously, they were called lipid cell tumors because of their high lipid content.[1,2] Two cases demonstrating occurrence of this rare ovarian tumor within the context of von Hippel-Lindau (VHL) disease have been reported.[2,3] VHL disease is an autosomal dominant familial inherited syndrome, with varied manifestations depending on the specific mutation. Pancreatic neuroendocrine tumors in association with pheochromocytoma are a classic phenotype of VHL disease,[3] but association with steroid tumor of the ovary is a very rare occurrence. A 17-year-old female with VHL, who had previously undergone adrenal sparing surgeries for bilateral pheochromocytomas, presented to our institution with hirsutism and menstrual irregularity. Serum testosterone was elevated at 269 ng/dL. She received regular screening per VHL alliance guidelines,[2] which included imaging of her abdomen, but not the pelvis. MRI showed a hypervascular pancreatic mass with central low signal, corresponding to a calcified pancreatic mass on CT, presumably the neuroendocrine tumor. No virilizing etiology was identified. So, MRI of the pelvis was performed, and this showed an enhancing right adnexal mass not seen separate from the ovary (Fig. 1). It showed drop of signal on pre-contrast T1-weighted (T1W) opposed phase (Fig. 2) compared to T1W in-phase imaging consistent with lipid content within the mass. The mass was later pathologically proven to be steroid cell tumor.
Fig. 1

Coronal post-contrast T1WI MRI of the pelvis showed an enhancing mass in the right adnexa (arrow), not seen separate from the right ovary. The uterus was normal. T1WI, T1-weighted image.

Fig. 2

Axial pre-contrast T1WI MRI of the pelvis demonstrating the same mass (arrows) seen on Fig. 1. It showed drop of signal on T1W opposed phase (right image) compared to T1W in-phase imaging (left image), consistent with lipid content within the mass. T1WI, T1-weighted image.

Although germ cell tumors (teratomas) are the most common lipid containing ovarian tumors, they rarely cause virilization. Lipid containing metastasis from clear cell renal cell cancer which can occur with VHL, is a rare possibility. However, these do not cause virilization, and the kidneys were normal in our case. Virilization and menstrual irregularity in our patient raised the suspicion of an androgen-producing ovarian tumor, with the differential diagnosis including Sertoli-Leydig cell tumors, Leydig cell tumors, steroid cell tumors, and less frequently, granulosa-theca tumor.[1] Rarely, nonfunctional ovarian tumors like epithelial cystadenomas or cystadenocarcinomas stimulate steroid production in the adjacent normal ovarian stroma and present with hyperandrogenism.[1] The combination of lipid content within the ovarian mass (as demonstrated by loss of signal on out-of-phase chemical shift imaging) with virilization pointed to the diagnosis of a steroid cell tumor. There is very little literature on the MRI features of lipid content within such a tumor, which in the setting of virilization and VHL, pointed to the diagnosis in our case. The treatment of choice for symptomatic abdominal tumors in VHL is generally organ sparing resection. Unfortunately, for this young patient with a genetic condition likely predisposing her to such ovarian tumors, she developed a second tumor in her contralateral ovary eventually needing resection of both ovaries. In conclusion, as most steroid cell ovarian tumors demonstrate high lipid content, exploiting the chemical shift artifact on dual echo gradient-echo (GRE) MRI due to this lipid content may help to clinch the diagnosis in the appropriate clinical context of virilizing features in a case of VHL disease with adnexal mass, as demonstrated in our case.
  3 in total

Review 1.  Duodenal carcinoid tumours, phaeochromocytoma and neurofibromatosis: islet cell tumour, phaeochromocytoma and the von Hippel-Lindau complex: two distinctive neuroendocrine syndromes.

Authors:  D F Griffiths; G T Williams; E D Williams
Journal:  Q J Med       Date:  1987-09

2.  Lipid cell tumors in two women with von Hippel-Lindau syndrome.

Authors:  Marnie Wagner; Hyacinth N Browne; W Marston Linehan; Maria Merino; Nabeel Babar; Pamela Stratton
Journal:  Obstet Gynecol       Date:  2010-08       Impact factor: 7.623

3.  Steroid cell tumor: a rare cause of hirsutism in a female.

Authors:  Jayshree Swain; Shruti Sharma; Ved Prakash; N K Agrawal; S K Singh
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2013-09-16
  3 in total
  4 in total

1.  Ovarian steroid cell tumor associated with von Hippel-Lindau syndrome: a report of two cases and literature review.

Authors:  Yulan Gong; Suad Taraif; Iryna Mazur; Amandeep Aneja; Min Huang; Debra L Somers; Jian J Fu
Journal:  Int J Clin Exp Pathol       Date:  2022-08-15

Review 2.  Ovarian solid tumors: MR imaging features with radiologic-pathologic correlation.

Authors:  Naoko Mukuda; Mana Ishibashi; Atsushi Murakami; Takeru Fukunaga; Shinya Fujii
Journal:  Jpn J Radiol       Date:  2020-04-27       Impact factor: 2.374

3.  Establishment and Verification of Logistic Regression Model for Qualitative Diagnosis of Ovarian Cancer Based on MRI and Ultrasound Signs.

Authors:  Xiao Guo; Guangcai Zhao
Journal:  Comput Math Methods Med       Date:  2022-02-15       Impact factor: 2.238

4.  Contrast-enhanced ultrasound of ovarian steroid cell tumor, not otherwise specified: A case report.

Authors:  Mai Sun; Bo Zhang
Journal:  Oncol Lett       Date:  2022-09-05       Impact factor: 3.111

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.